References

SLIDE 3

1. American Cancer Society. Cancer Facts and Figures 2006. www.cancer.org/downloads/STT/CAFF2006PWSecured.pdf. Accessed January 5, 2007.

SLIDE 4

1. Ries LAG, Eisner MP, Kosary CL, et al, eds. SEER Cancer Statistics Review, 1975-2002. Bethesda, MD: National Cancer Institute; 2005.
   http://seer.cancer.gov/csr/1975_2002. Accessed January 2, 2007.
2. National Institutes of Health. Colorectal Cancer (PDQ^®): Treatment. www.cancer.gov/cancertopics/pdq/treatment/colon/patient/. Accessed January 5, 2007.
3. Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 2001;91:854-862.
4. Sachar DB. Cancer in Crohn’s disease: dispelling the myths. Gut. 1994;35:1507-1508.

SLIDE 5

1. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526-535.
2. Jayaram H, Satsangi J, Chapman RW. Increased colorectal dysplasia in chronic ulcerative colitis complicated by primary sclerosing cholangitis: fact or fiction? Gut. 2001;48:430-434.
3. Itzkowitz SH, Present DH; for the Crohn’s & Colitis Foundation of America Colon Cancer in IBD Study Group. Consensus Conference: Colorectal Cancer Screening and Surveillance in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2005;11:314-321.

SLIDE 8

1. American Cancer Society. Colorectal Cancer: Early Detection. www.cancer.org/docroot/CRI/content/CRI_2_6X_Colorectal_Cancer
   _Early_Detection_10.asp. Accessed January 5, 2007.

SLIDE 9

1. The American College of Gastroenterology. Colorectal Cancer Screening. www.gi.org/patients/gihealth/colon.asp. Accessed January 5, 2007.
2. Peipins LA, Sandler RS. Epidemiology of colorectal adenomas. Epidemiol Rev. 1994;16:273-297.

SLIDE 10

1. Itzkowitz SH, Harpaz N. Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology. 2004;126:1634-1648.

SLIDE 11

1. Kornbluth A, Sachar DB; and the Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2004;99:1371-1385.

SLIDE 12

1. Itzkowitz SH, Harpaz N. Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology. 2004;126:1634-1648.

SLIDE 13

1. National Institutes of Health. Cancer of the Colon and Rectum: Symptoms. www.cancer.gov/cancertopics/wyntk/colon-and-rectum/page6. Accessed January 5, 2007.

SLIDE 14

1. Goessling W, Mayer RJ. Systemic treatment of patients who have colorectal cancer and inflammatory bowel disease. Gastroenterol Clin North Am. 2006;35:713-727.

SLIDE 15

1. Colorectal Cancer Initiatives, 2006/2007. From the Division of Cancer Prevention and Control. Centers for Disease Control and Prevention.
   www.cdc.gov/cancer/colorectal/pdf/0607_colorectal_fs.pdf. Accessed January 5, 2007.
2. Selby JV, Friedman GD, Quesenberry CP Jr, Weiss NS. A case control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med. 1992;326:653-657.

SLIDES 16 and 17

1. American Cancer Society. Colorectal Cancer: Early Detection. www.cancer.org/docroot/CRI/content/CRI_2_6X_Colorectal_Cancer
   _Early_Detection_10.asp. Accessed January 5, 2007.
2. U.S. Preventive Services Task Force. Screening for Colorectal Cancer: Summary of Recommendations. www.ahrq.gov/clinic/uspstf/uspscolo.htm. Accessed January 5, 2007.
3. Winawer SJ, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale: update based on new evidence. Gastroenterology. 2003;124:544-560.

SLIDE 20

1. Pignone M, Rich M, Teutsch SM, et al. Screening for colorectal cancer in adults at average risk: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;137:132-141.

SLIDE 22

1. Itzkowitz SH, Present DH; for the Crohn’s & Colitis Foundation of America Colon Cancer in IBD Study Group. Consensus Conference: Colorectal Cancer Screening and Surveillance in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2005;11:314-321.

SLIDE 23

1. Bernstein CN, Shanahan F, Weinstein WM. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? Lancet. 1994;343:71-74.

SLIDE 25

1. O’Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer Sixth Edition Staging. J Natl Cancer Inst. 2004;96:1420-1425.

SLIDE 26

1. Centers for Disease Control and Prevention. Morbidity and Mortality Weekly Report (MMWR). Synopsis for March 14, 2003. www.cdc.gov/od/oc/media/mmwrnews/n030314.htm. Accessed January 5, 2007.
2. O’Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer Sixth Edition Staging. J Natl Cancer Inst. 2004; 96:1420-1425.

SLIDE 27

1. Vainio H, Bianchini F, eds. IARC Handbooks of Cancer Prevention, Vol 6: Weight Control and Physical Activity. Lyon, France: IARC Press; 2002.
2. Curry S, Byers T, Hewitt M, eds. Fulfilling the Potential of Cancer Prevention and Early Detection. Washington, DC: The National Academies Press; 2003.
3. Larsson SC, Wolk A. Meat consumption and risk of colorectal cancer: a meta-analysis of prospective studies. Int J Cancer Inst. 2006;119:2657-2664.

SLIDE 30

1. National Institutes of Health. Colorectal Cancer (PDQ^®): Prevention. www.cancer.gov/cancertopics/pdq/prevention/colorectal/
   healthprofessional/page3. Accessed January 5, 2007.

SLIDE 31

1. Freudenheim JL, Graham S, Marshall JR, et al. Folate intake and carcinogenesis of the colon and rectum. Int J Epidemiol. 1991; 20:368-374.
2. Giovannucci E, Stampfer MJ, Colditz GA, et al. Folate, methionine, and alcohol intake and risk of colorectal adenoma. J Natl Cancer Inst. 1993;85:875-884.
3. Tseng M, Murray SC, Kupper LL, Sandler RS. Micronutrients and the risk of colorectal adenomas. Am J Epidemiol. 1996; 144:1005-1014.
4. Baron JA, Beach M, Mandel JS, et al. Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group. N Engl J Med. 1999;340:101-107.
5. Bonithon-Kopp C, Kronborg O, Giacosa A, et al. Calcium and fibre supplementation in prevention of colorectal adenoma recurrence: a randomised intervention trial. Lancet. 2000; 356:1300-1306.

SLIDE 32

1. Chan EP, Lichtenstein GR. Chemoprevention: risk reduction with medical therapy of inflammatory bowel disease. Gastroenterol Clin North Am. 2006;35:675-712.
2. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol. 2005;100:1345-1353.
3. Sinicrope F. Is ursodeoxycholic acid effective for the prevention of colorectal adenoma recurrence? Nature Clin Pract Gastroenterol Hepatol. 2005;2:512-513.

SLIDE 33

1. van Bodegraven AA, Terhaar sive Droste JS. Mesalazine therapy and ulcerative colitis: a long-term friendship. Eur Gastroenterology Rev. 2005. www.touchbriefings.com/pdf/1489/Bodegraven.pdf. Accessed January 2, 2007.

SLIDES 34, 35, and 36

1. Hall A, Porrett T, Cox C. Factors affecting medication compliance in inflammatory bowel disease. Gastrointestinal Nurs. 2006;4:31-40.
2. Lopez-Sanroman A, Bermejo F. Review article: how to control and improve adherence to therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2006;24(Suppl 3):45-49.
3. Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2006;23:577-585.